What is the mechanism by which NSAIDs contribute to gastric ulcers?

What is the mechanism by which NSAIDs contribute to gastric ulcers?

• A. Inhibition of Cox2
• B. Inhibition of Cox1
• C. Inhibition of platelet aggregation
• D. Stimulation of gastric acid production

Answer: (B)

Nonsteroidal anti-inflammatory drugs (NSAIDs) can contribute to the development of gastric ulcers primarily through the inhibition of cyclooxygenase-1 (Cox-1). Cox-1 is an enzyme that plays a crucial role in the production of prostaglandins, which are compounds that help maintain the protective lining of the stomach. These prostaglandins promote mucosal defense mechanisms, including stimulating the secretion of mucus and bicarbonate, as well as maintaining blood flow to the gastric mucosa. When NSAIDs inhibit Cox-1, the reduced levels of these protective prostaglandins can lead to decreased mucus production and impaired gastric mucosal defenses. This can result in increased susceptibility of the gastric lining to injury from gastric acid, ultimately leading to the formation of ulcers. This mechanism contrasts with Cox-2 inhibition, which primarily reduces inflammation and pain but has less direct impact on gastric mucosal protection. While inhibition of platelet aggregation can occur with some NSAIDs due to Cox-1 inhibition, the primary concern regarding gastric ulcers is the loss of mucosal protection, not the platelet effect. Stimulation of gastric acid production is not a direct effect of NSAIDs; instead, it is the reduction in defense mechanisms that contributes to ulcer formation

Nonsteroidal anti-inflammatory drugs (NSAIDs) can contribute to the development of gastric ulcers primarily through the inhibition of cyclooxygenase-1 (Cox-1). Cox-1 is an enzyme that plays a crucial role in the production of prostaglandins, which are compounds that help maintain the protective lining of the stomach. These prostaglandins promote mucosal defense mechanisms, including stimulating the secretion of mucus and bicarbonate, as well as maintaining blood flow to the gastric mucosa.

When NSAIDs inhibit Cox-1, the reduced levels of these protective prostaglandins can lead to decreased mucus production and impaired gastric mucosal defenses. This can result in increased susceptibility of the gastric lining to injury from gastric acid, ultimately leading to the formation of ulcers.

This mechanism contrasts with Cox-2 inhibition, which primarily reduces inflammation and pain but has less direct impact on gastric mucosal protection. While inhibition of platelet aggregation can occur with some NSAIDs due to Cox-1 inhibition, the primary concern regarding gastric ulcers is the loss of mucosal protection, not the platelet effect. Stimulation of gastric acid production is not a direct effect of NSAIDs; instead, it is the reduction in defense mechanisms that contributes to ulcer formation